2026 Pediatric Rheumatology Symposium

March 18-21, 2026. Minneapolis, MN.

View by Number View by Title View Sessions

Abstract Number: 107

Targeting Macrophage Activation Syndrome (MAS) in Systemic Juvenile Idiopathic Arthritis (sJIA): Real-World Emapalumab Experience Spanning 3 Years
Abstract Number: 108

Gender Diverse Youth Treatment Response to Amplified Musculoskeletal Pain Syndrome Rehabilitation
Abstract Number: 109

Tarsitis in Juvenile Idiopathic Arthritis: Clinical characteristics, imaging features, and treatment Response – A multicenter retrospective study
Abstract Number: 110

Juvenile Idiopathic Inflammatory Myopathies and Macrophage Activation Syndrome: A Case Series
Abstract Number: 111

Pediatric chronic nonbacterial osteomyelitis outcomes after NSAID or TNF inhibitor discontinuation, a registry cohort with two year follow up data
Abstract Number: 112

Burden of Latent and Active TB in Pediatric TNF-Inhibitor Therapy: A Decade of Real-World Data from a Tertiary Care Centre
Abstract Number: 113

Risk Assessment for Pediatric Rheumatic Diseases in Children with a History of Kawasaki Disease: A Long-Term Retrospective Comparative Big Data Cohort Study
Abstract Number: 114

Incidence of Inflammatory Arthritis Before and After Inflammatory Bowel Disease Diagnosis: A Population-Based Cohort Study
Abstract Number: 115

KneeMS for Juvenile Idiopathic Arthritis
Abstract Number: 116

Pilot of Adalimumab Withdrawal (PAW): Preliminary Analysis of Feasibility and Acceptability of Self-Collected Capillary Blood Samples
Abstract Number: 117

Reliability of Pediatric-Specific Musculoskeletal Ultrasound Scanning Protocol for the Detection of Arthritis
Abstract Number: 118

Pain Experience and Treatment in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Systemic Lupus Erythematosus Registry
Abstract Number: 119

Expansion of Mental Health Screening to Patients with Diverse Rheumatologic Diagnoses in an Outpatient Pediatric Rheumatology Clinic
Abstract Number: 120

Bridging Evidence and Practice: New Institutional Pathway Increases Primary Intensification Rates for Children with High-Risk Kawasaki Disease
Abstract Number: 121

Representation of Skin of Color Among Pediatric Images in ACR Image Library

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].